AMGN Stock Down Despite Strong Data From Obesity Drug Study

Key TakeawaysA new Amgen weight reduction drug, MariTide, has bred successful results after a 52-week study.Still, AMGN stock declined almost 5% on Tuesday as weight loss reduction was at the lower end of expectations.Register now to see our 7 Best Stocks for the Next 30 Days report - free today!Amgen (AMGN) announced the much-awaited 52-week top-line data from a phase II study on MariTide, its GLP-1 therapy being developed for obesity and related conditions.The data showed that MariTide led to sustainable ...